🇺🇸 GW642444 Inhalation Powder in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Obstructive Pulmonary Disease — 7 reports (36.84%)
  2. Pneumonia — 4 reports (21.05%)
  3. Angina Unstable — 1 report (5.26%)
  4. Aortic Aneurysm — 1 report (5.26%)
  5. Atrial Fibrillation — 1 report (5.26%)
  6. Atrial Flutter — 1 report (5.26%)
  7. Bladder Neoplasm — 1 report (5.26%)
  8. Blood Chloride Decreased — 1 report (5.26%)
  9. Blood Sodium Decreased — 1 report (5.26%)
  10. Cardiomyopathy — 1 report (5.26%)

Source database →

Other Respiratory / Pulmonology approved in United States

Frequently asked questions

Is GW642444 Inhalation Powder approved in United States?

GW642444 Inhalation Powder does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GW642444 Inhalation Powder in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.